These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17642499)

  • 1. Potential of commercial anti-D reagents in the identification of partial D variants in Indian population.
    Kulkarni SS; Vasantha K; Gupte SC; Mohanty D; Ghosh K
    Indian J Med Res; 2007 May; 125(5):641-4. PubMed ID: 17642499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commercial anti-D reagents in Indian market & detection of partial D variants.
    Choudhury N
    Indian J Med Res; 2007 May; 125(5):615-7. PubMed ID: 17642496
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoclonal reagents for rhesus-D typing of Irish patients and donors: a review.
    Williams M
    Br J Biomed Sci; 2000; 57(2):142-9. PubMed ID: 10912289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varied distribution of RhD epitopes in the Indian population.
    Kulkarni SS; Gupte SC; Vasantha K; Mohanty D; Ghosh K
    Natl Med J India; 2007; 20(4):169-71. PubMed ID: 18085120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reactivity of monoclonal antibodies as blood grouping reagents].
    Okubo Y
    Nihon Rinsho; 1997 Sep; 55(9):2340-6. PubMed ID: 9301300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention.
    Denomme GA; Wagner FF; Fernandes BJ; Li W; Flegel WA
    Transfusion; 2005 Oct; 45(10):1554-60. PubMed ID: 16181204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of weak D in blood donors typed as D positive by the Olympus PK 7200.
    Jenkins CM; Johnson ST; Bellissimo DB; Gottschall JL
    Immunohematology; 2005; 21(4):152-4. PubMed ID: 16472016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivity of FDA-approved anti-D reagents with partial D red blood cells.
    Judd WJ; Moulds M; Schlanser G
    Immunohematology; 2005; 21(4):146-8. PubMed ID: 16472014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weak D phenotypes and transfusion safety: where do we stand in daily practice?
    Noizat-Pirenne F; Verdier M; Lejealle A; Mercadier A; Bonin P; Peltier-Pujol F; Fialaire-Legendre A; Tournamille C; Bierling P; Ansart-Pirenne H
    Transfusion; 2007 Sep; 47(9):1616-20. PubMed ID: 17725725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serologic and molecular characterization of D variants in Brazilians: impact for typing and transfusion strategy.
    Credidio DC; Pellegrino J; Castilho L
    Immunohematology; 2011; 27(1):6-11. PubMed ID: 22356480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple diagnostic strategy for RhD typing in discrepant cases in the Indian population.
    Kulkarni S; Kasiviswanathan V; Ghosh K
    Blood Transfus; 2013 Jan; 11(1):37-42. PubMed ID: 22871818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric quantification of antigen D sites on red blood cells of partial D and weak D variants in India.
    Kulkarni S; Mohanty D; Gupte S; Vasantha K; Joshi S
    Transfus Med; 2006 Aug; 16(4):285-9. PubMed ID: 16879157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rh discrepancies caused by variable reactivity of partial and weak D types with different serologic techniques.
    Denomme GA; Dake LR; Vilensky D; Ramyar L; Judd WJ
    Transfusion; 2008 Mar; 48(3):473-8. PubMed ID: 18067505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel weak D types 31 and 32: adsorption-elution-supported D antigen analysis and comparison to prevalent weak D types.
    Körmöczi GF; Förstemann E; Gabriel C; Mayr WR; Schönitzer D; Gassner C
    Transfusion; 2005 Oct; 45(10):1574-80. PubMed ID: 16181207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of anti-D monoclonal antibody reagents based on their reactivity with the weak D phenotype.
    Lai M; Grasso C; Boschi I; D'Onofrio G; Pascali V; Leone G
    Transfusion; 2009 May; 49(5):937-42. PubMed ID: 19175552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An International Standard for specifying the minimum potency of anti-D blood-grouping reagents: evaluation of a candidate preparation in an international collaborative study.
    Thorpe SJ; Fox B; Heath AB; Scott M; de Haas M; Kochman S; Padilla A
    Vox Sang; 2006 Feb; 90(2):131-9. PubMed ID: 16430672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. False-positive reactions of some monoclonal anti-c reagents.
    Strobel E; Bauer MF
    Transfus Med; 2009 Jun; 19(3):141-5. PubMed ID: 19566672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weak D type 1.1 exemplifies another complexity in weak D genotyping.
    Doescher A; Flegel WA; Petershofen EK; Bauerfeind U; Wagner FF
    Transfusion; 2005 Oct; 45(10):1568-73. PubMed ID: 16181206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary anti-D immunization by Del red blood cells.
    Yasuda H; Ohto H; Sakuma S; Ishikawa Y
    Transfusion; 2005 Oct; 45(10):1581-4. PubMed ID: 16181208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A RhD negative patient failed to produce detectable anti-D after transfusion of 35 units of RhD positive red blood cells].
    Lee WM; Kim JH; Ha JS; Ryoo NH; Jeon DS; Kim JR; Cho D
    Korean J Lab Med; 2007 Oct; 27(5):369-72. PubMed ID: 18094603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.